Vinge advises Ramirent AB in connection with its acquisition of JIAB Hyrcenter (consisting of the companies JIAB Hyrcenter AB and JIAB Boden AB). Ramirent thereby further strengthens its position in Norrbotten and as the largest machine rental company in Sweden.
Vinge has, together with Norton Rose Fulbright, advised Anglo American Limited in connection with entering into a royalty agreement of USD 10 million and a binding term sheet for an offtake agreement with Dannemora Iron AB. Moreover, Vinge has assisted with thereto related due diligence. Dannemora Iron AB is a wholly owned subsidiary of Grängesberg Exploration Holding AB (publ).
Vinge advises Dreams AB in connection with the divestment of the leading engagement banking platform Dreams Technology to Doconomy which expands suite of climate action tools and empowers banks to better engage their customers.
Immunovia AB (publ) is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Immunovia’s shares are listed on Nasdaq Stockholm.
Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.
Vinge has advised Neobo Fastigheter AB (publ) (”Neobo”) in connection with the listing of Neobo’s shares on Nasdaq First North Premier. The company description was published on 6 February 2023 and the first day of trading on Nasdaq First North Premier was on 10 February 2023.
Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.